Changing the scale of what’s possible…
Nautilus Biotechnology seeks to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. By integrating breakthrough innovations in computer science, engineering, and biochemistry, we are developing a large-scale, single-molecule proteomic analysis technology that aims to deliver extreme sensitivity and scale.
By enabling an expansion of both the depth and breadth of proteomic studies, Nautilus’ technology has the potential to revolutionize how biological research is conducted, drugs are identified and developed, and human disease is treated.
Nautilus Technology
To understand the extraordinary complexity of the ever-changing proteome, we are developing a large scale, single-molecule proteome analysis platform that aims to deliver the speed, simplicity, accuracy and versatility we believe is necessary to set new expectations and change the scale of what’s possible.
The Need for a Breakthrough in Proteomics
New Therapies
Since 2002, there has been a nearly three-fold increase in R&D spending. However, during that same period, there has not been a proportional increase in the number of new drugs approved each year. A dramatic increase in proteomics sensitivity could lead to more efficient, cost effective and successful R&D efforts.
Diagnostics
As we begin to scratch the surface of the true complexity and nuance of human health and disease, a breakthrough increase in proteomics analysis throughput will allow researchers to measure at the scale needed to power the studies needed to quickly and cost effectively discover these new diagnostic tools.
Basic Science Research
The inability to easily and reliably quantify proteins has limited our understanding of cellular and organismic biology. The democratization of proteomics could open a wider range of inquiries, accelerating research and increasing proteomics-based publications.
“After many years of trying to optimize traditional proteomic workflows, we set out to create an entirely new and transformational platform capable of making it easy for anyone to access comprehensive, quantitative measurements of the human proteome.”
Dr. Parag Mallick
Chief Scientist and Founder, Nautilus Biotechnology
